Is PayPal Stock Finally a Buy?
Shares of online payment giant PayPal (NASDAQ:PYPL) have struggled over…
Sell
39
CORT Quote, Financials, Valuation and Earnings
Last price:
$74.00
Seasonality move
:
5.53%
Day range:
$71.52 - $74.03
52-week range:
$49.00 - $117.33
Dividend yield:
0%
P/E ratio:
84.23x
P/S ratio:
11.89x
P/B ratio:
12.27x
Volume:
646.9K
Avg. volume:
880.5K
1-year change:
35.76%
Market cap:
$7.8B
Revenue:
$675M
EPS (TTM):
$0.88
Analysts' Opinion
-
Consensus RatingCorcept Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $135.25, Corcept Therapeutics, Inc. has an estimated upside of 83.47% from its current price of $73.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $121.00 representing 100% downside risk from its current price of $73.72.
Fair Value
-
According to the consensus of 2 analysts, Corcept Therapeutics, Inc. has 83.47% upside to fair value with a price target of $135.25 per share.
CORT vs. S&P 500
-
Over the past 5 trading days, Corcept Therapeutics, Inc. has overperformed the S&P 500 by 2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Corcept Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Corcept Therapeutics, Inc. has grown year-over-year revenues for 18 quarters straight. In the most recent quarter Corcept Therapeutics, Inc. reported revenues of $207.6M.
Earnings Growth
-
Corcept Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Corcept Therapeutics, Inc. reported earnings per share of $0.16.
Enterprise value:
7.3B
EV / Invested capital:
11.50x
Price / LTM sales:
11.89x
EV / EBIT:
111.93x
EV / Revenue:
9.90x
PEG ratio (5yr expected):
6.39x
EV / Free cash flow:
45.15x
Price / Operating cash flow:
54.21x
Enterprise value / EBITDA:
108.82x
Gross Profit (TTM):
$727.8M
Return On Assets:
12.77%
Net Income Margin (TTM):
14.12%
Return On Equity:
16%
Return On Invested Capital:
15.84%
Operating Margin:
4.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $450M | $628.6M | $741.2M | $182.5M | $207.6M | |
| Gross Profit | $443.9M | $618.8M | $727.8M | $179.7M | $203M | |
| Operating Income | $98.1M | $143.4M | $65.6M | $46.6M | $10.2M | |
| EBITDA | $100.6M | $144.8M | $67.4M | $47.1M | $10.7M | |
| Diluted EPS | $0.81 | $1.26 | $0.88 | $0.41 | $0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $401.9M | $452.4M | $431.5M | $467M | $541.1M | |
| Total Assets | $585.4M | $533.3M | $594M | $784.3M | $823.6M | |
| Current Liabilities | $44.8M | $53.1M | $121.9M | $126.2M | $172.3M | |
| Total Liabilities | $45.2M | $59.9M | $132.3M | $145.4M | $191.7M | |
| Total Equity | $540.2M | $473.4M | $461.7M | $638.8M | $631.9M | |
| Total Debt | $1M | -- | -- | $6.4M | $5.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $154.5M | $144.7M | $162.8M | $73.8M | $54.5M | |
| Cash From Investing | $56.6M | -$96.1M | $17.2M | -$44M | $14.6M | |
| Cash From Financing | -$149.6M | -$23M | -$193.7M | -$21.1M | -$46.4M | |
| Free Cash Flow | $154.4M | $142.6M | $162.6M | $72.2M | $54.5M | |
CORT
Sector
Market Cap
$7.8B
$28.8M
Price % of 52-Week High
62.83%
49.55%
Dividend Yield
0%
0%
Shareholder Yield
1.72%
-1.29%
1-Year Price Total Return
35.76%
-24.88%
Beta (5-Year)
0.431
0.575
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$73.31
200-day SMA
Buy
Level
$70.99
Bollinger Bands (100)
Sell
Level
68.5 - 79.32
Chaikin Money Flow
Buy
Level
5.6M
20-day SMA
Sell
Level
$74.12
Relative Strength Index (RSI14)
Sell
Level
46.56
ADX Line
Sell
Level
25.4
Williams %R
Neutral
Level
-40.3197
50-day SMA
Sell
Level
$76.82
MACD (12, 26)
Sell
Level
-1.11
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
8.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (22.4621)
Buy
CA Score
(Annual)
Level (2.1717)
Sell
Beneish M-Score
(Annual)
Level (-2.0331)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.099)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, CORT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CORT average analyst price target in the past 3 months is $135.25.
-
Where Will Corcept Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Corcept Therapeutics, Inc. share price will rise to $135.25 per share over the next 12 months.
-
What Do Analysts Say About Corcept Therapeutics, Inc.?
Analysts are divided on their view about Corcept Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corcept Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $121.00.
-
What Is Corcept Therapeutics, Inc.'s Price Target?
The price target for Corcept Therapeutics, Inc. over the next 1-year time period is forecast to be $135.25 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CORT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Corcept Therapeutics, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CORT?
You can purchase shares of Corcept Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corcept Therapeutics, Inc. shares.
-
What Is The Corcept Therapeutics, Inc. Share Price Today?
Corcept Therapeutics, Inc. was last trading at $74.00 per share. This represents the most recent stock quote for Corcept Therapeutics, Inc.. Yesterday, Corcept Therapeutics, Inc. closed at $73.72 per share.
-
How To Buy Corcept Therapeutics, Inc. Stock Online?
In order to purchase Corcept Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CORT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CORT
Sector
P/E ratio
84.23x
23.09x
PEG ratio
6.39x
-0.01x
P/B ratio
12.27x
1.84x
Price / LTM sales
11.89x
1.58x
Growth Metrics
CORT
Sector
Revenue growth
13.75%
5.49%
Earnings growth
-60.52%
2.22%
Revenue (5-year growth)
17.11%
6.46%
Earnings forecast
$0.14
-$0.20
Profitability
CORT
Sector
Profitability FY 2024
$664.2M
$3.8M
Return on invested capital
15.84%
-30.03%
Return on assets
12.77%
-27.12%
Return on equity
16%
-35.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
3
Balance Sheet
CORT
Sector
Total cash
$421.7M
$28.1M
Short term investments
$255.7M
$26M
Total assets
$840.6M
$80.8M
Long term debt
$5.3M
$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Sprouts Stock Fall So Much?
Shares of health-oriented grocery chain Sprouts Farmers Market (NASDAQ:SFM) have…
Why Did Amazon Go Up So Much?
Shares of Amazon (NASDAQ:AMZN) soared late last week, bringing the…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 36x
Alerts
Buy
100
GMED alert for Nov 10
Globus Medical, Inc. [GMED] is up 1.66% over the past day.
Buy
73
GCT alert for Nov 10
GigaCloud Technology, Inc. [GCT] is up 0.72% over the past day.
Buy
84
FROG alert for Nov 10
JFrog Ltd. [FROG] is up 7.83% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
